Search

Displaying results 6441 - 6450 of 7181 in total
  1. Drug

    JNJ-17216498

    go.drugbank.com/drugs/DB17087
    Investigational

    JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.[A253997]

  2. Drug

    E59

    go.drugbank.com/drugs/DB18372
    Experimental

    It was developed by Sixal Inc.

  3. Drug

    AZD-9684

    go.drugbank.com/drugs/DB05712
    Experimental

    It is being developed by AstraZeneca.

  4. Drug

    ALKS 29

    go.drugbank.com/drugs/DB05723
    Experimental

    It is being developed by Alkermes, Inc.

  5. Drug

    PLT012

    go.drugbank.com/drugs/DB23610
    Investigational

    PLT012 is a humanized anti-CD36 antibody developed by Pilatus Biosciences for treating liver cancer and intrahepatic bile duct cancer.

  6. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    It is being developed by Ascent Therapeutics.

  7. Drug

    (1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide

    go.drugbank.com/drugs/DB08260
    Experimental

    (1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide is a solid. This compound belongs to the oxepanes.

    Synonyms: (1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide
  8. Drug

    Forasartan

    go.drugbank.com/drugs/DB01342
    Experimental

    Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension.

  9. Drug

    Xeruborbactam

    go.drugbank.com/drugs/DB21512
    Investigational

    Xeruborbactam is under investigation in clinical trial NCT07104162 (A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment).

  10. Drug

    Gridegalutamide

    go.drugbank.com/drugs/DB21593
    Investigational

    Gridegalutamide is under investigation in clinical trial NCT04428788 (Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer).